Pharmacoeconomic Evaluation of Polyethylene Glycol Losenatide for the Treatment of Type 2 Diabetes Mellitus Based on Markov Modeling
1. Department of Medicine, Faculty of Chinese Medicine Science, Guangxi University of Chinese Medicine, Nanning 530222, China
2. Graduate School, Guangxi University of Chinese Medicine, Nanning 530222, China
| Abstract: | Objective An economic evaluation of polyethylene glycol losenatide (PEX168) for the treatment of type 2 diabetes mellitus (T2DM). Methods Based on clinical trial data, Markov models were constructed to simulate and predict the long-term cost and utility of each regimen of placebo, PEX168/100 μg, and PEX168/200 μg. Results After simulating 30 years of disease progression, patients in the PEX168/100 μg and PEX168/200 μg groups had a 2.72% and 18% reduction in mortality compared to the placebo group, respectively. Treatment with PEX168/100 μg and PEX168/200 μg increased the utility value by 3.96, 8.21 QALYs with ICER of $20,551.53/QALYs and $25,218.80/QALYs, respectively, which is less than the threshold (λ) i.e., $85,698, and the increase in cost is acceptable, as compared to the placebo group. The results of the sensitivity analysis with cost ± 20%, utility value ± 10%, and discount rate 0 to 8% adjustments verified the stability of the model. The results of the probabilistic sensitivity analysis showed that the probability that PEX168/100 μg and PEX168/200 μg are economical when the willingness-to-pay value is λ is 99.99%. and that treatment with PEX168/200μg was more cost-utility than PEX168/100μg. Conclusion For patients with T2DM, treatment with PEX168 is the more cost-utility option. |
| Keywords: | Polyethylene Glycol Losenatide; Type 2 Diabetes Mellitus; Cost-utility; Markov Modeling |
| DOI: | 10.57237/j.mrf.2024.03.002 |
View:
Downloads:
Received: 7 October 2024
Accepted: 20 November 2024
Published Online: 5 December 2024
Funding
| 1. | 广西中医药大学赛恩斯新医药学院科研项目 (编号: 2022CX004, 2022MS008, 2022QJ001) |
| 2. | 广西中医药大学赛恩斯新医药学院国家级大学生创新训练项目 (编号: 202413643007) |
References
| [1] | 魏成, 王梦龙, 徐瑶, 张记收, 赵蒙蒙, 郑资辉, 万军. 1990~2019年中国人群2型糖尿病疾病负担及其危险因素分析 [J]. 中国循证心血管医学杂志, 2023, 15(06): 657-661+666. |
| [2] | Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022 Jan; 183: 109119. |
| [3] | Strain WD, Paldánius PM. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol. 2018 Apr 18; 17(1): 57. Erratum in: Cardiovasc Diabetol. 2021 Jun 11; 20(1): 120. |
| [4] | 吴秀强, 戴小华, 杨珍, 谢志勤, 陈诗涵, 王泽权, 易林霞. 全球糖尿病负担的社会经济差异: 1990—2019年时间趋势的分析 [J]. 现代预防医学, 2024, 51(02): 210-215. |
| [5] | 刘春, 王怀斌, 吴佳. 基于DRGs的三级综合医院2型糖尿病患者住院费用标准研究 [J]. 中国卫生统计, 2024, 41(01): 139-142. |
| [6] | Shuai Y, Yang G, Zhang Q, Li W, Luo Y, Ma J, Chen D, Yang J, Wang X, Hu J, Xu N, Yang W. Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial. Diabetes Obes Metab. 2021 Jan; 23(1): 116-124. |
| [7] | Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998 Apr; 13(4): 397-409. |
| [8] | 袁虹. 2型糖尿病并发症对患者年治疗费用负担的影响分析 [J]. 中国医药指南, 2015, 13(14): 21-22. |
| [9] | 宋安民. 两种方案治疗2型糖尿病的效价比分析 [J]. 糖尿病新世界, 2016, 19(06): 67-68. |
| [10] | Liu Y, Ning X, Zhang L, Long J, Liang R, Peng S, Wang H, Li Y, Chen W, Xiao H. Prevalence of long-term complications in inpatients with diabetes mellitus in China: a nationwide tertiary hospital-based study. BMJ Open Diabetes Res Care. 2022 May; 10(3): e002720. |
| [11] | Clark CM Jr. The burden of chronic hyperglycemia. Diabetes Care. 1998 Dec; 21 Suppl 3: C32-4. |
| [12] | 周挺, 马爱霞, 付露阳. 药物经济学评价 Markov模型中转移概率计算的探讨 [J]. 中国卫生经济, 2017, 36(12): 40-42. |
| [13] | Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care. 2002 Mar; 25(3): 458-63. |
| [14] | 刘国恩. 中国药物经济学评价指南2020 [M]. 北京: 中国市场出版社, 2020: 27-28, 45-47. |
| [15] | 熊朝刚, 朱玉蓉, 李颖, 等. 恩格列净与二甲双胍联合治疗2型糖尿病的药物经济学评价 [J]. 中国医院药学杂志, 2021, 41(09): 880-885. |
| [16] | 马博乐, 赵振宇. 基于Markov模型的聚乙二醇洛塞那肽与二甲双胍联合治疗2型糖尿病的药物经济学评价 [J]. 中国医院药学杂志, 2023, 43(19): 2194-2197+2207. |
Join the Editorial Board
We invite active, qualified and high profile scientists and researchers to join as Editorial Board Members.
Join UsBecome a Reviewer
Scholars with a strong interest in reviewing are invited to join the reviewer panel to ensure the quality of the research to be published.
Join Us